Samuel Broder
Samuel Broder (born in 1945) is an American oncologist and medical researcher. He was a co-developer of some of the first effective drugs for the treatment of AIDS and was Director of the National Cancer Institute (NCI) from 1989 to 1995.

During the first years of the AIDS epidemic, he co-developed zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), which were the first effective drugs licensed for the treatment of AIDS. In 1989, he was appointed by President Ronald Reagan to be Director of the NCI. In this position he oversaw the development of a number of new therapies for cancer including paclitaxel (Taxol). After leaving the NCI, Dr. Broder became Senior Vice President for Research and Development at the IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics. He is now Chief Medical Officer of Celera.

He has received a number of honors for his work including the Arthur S. Flemming Award and the Leopold Griffuel Award.
Q162555
oncologist
Concept
Q2752427
medical researcher
Concept
Q12199
AIDS
DIS
Q664846
National Cancer Institute
LOC
Q12199
AIDS
DIS
Q198504
zidovudine
Concept
Q422606
didanosine
Concept
Q2344582
zalcitabine
Concept
Q9960
Ronald Reagan
PER
Q423762
paclitaxel
Concept
Q643341
Celera
ORG
Q4800207
Arthur S. Flemming Award
MEDIA
Q16240844
Samuel Broder
PER
1945-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1945
DATE
1989-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1989
DATE
1995-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1995
DATE
1989-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1989
DATE
1998-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1998
DATE
employer
employer
award received
medical condition treated
medical condition treated
medical condition treated